Sistemic announces companion biomarker programme

Published: 4-Jul-2011
Research & Development

Extends miRNA drug discovery toolkit

Sistemic, a global company with expertise in microRNA, has released a new companion biomarker programme, which extends its SistemRNA suite of drug discovery and development tools.

The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

See more

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Read more
Cell therapy companies to be offered a streamlined process for clinical trials

Trending Articles

  1. Hongene to support SiranBio siRNA candidate programme with CDMO services The RNA specialist will support SiranBio's SA1211 programme, helping advance the siRNA candidate through its vertically integrated CDMO services to address the complex nature of the next-gen therapeutic
  2. Scientists develop new technique to fight antimicrobial resistance The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
  3. Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
  4. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  5. Precision meets innovation in melting point determination Advancing analytical accuracy with automated thermal analysis

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Hi Tech Manufacturing

Hongene to support SiranBio siRNA candidate programme with CDMO services

The RNA specialist will support SiranBio's SA1211 programme, helping advance the siRNA candidate through its vertically integrated CDMO services to address the complex nature of the next-gen therapeutic
Research & Development

Reacta Healthcare announces expansion into Asia-Pacific and appoints Professor Gary Wing-Kin Wong to advisory board

Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint
Subscribe now